Human melanoma cells do not express Fas (Apo-1/CD95) ligand

被引:0
作者
Chappell, DB
Zaks, TZ
Rosenberg, SA
Restifo, NP
机构
[1] NCI, Surg Branch, NIH, Bethesda, MD 20892 USA
[2] Howard Hughes Med Inst, NIH, Res Scholars Program, Bethesda, MD 20814 USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A recent report described the expression of Fas ligand (FasL) by melanoma cells as an important mechanism involved in the immune evasion by tumors [M, Hahne et al., Science (Washington DC), 274: 1363-1366, 1996], To investigate the expression of Fast by melanomas, we screened a panel of early-passage cell lines by functional assay and reverse transcriptase-PCR. Using conditions designed to replicate those in the original report, we did not find functional Fast on any of the 19 human melanoma lines established at the National Cancer Institute. Furthermore, we additionally evaluated our melanoma lines using reverse transcriptase-PCR and found that 0 of the 26 human melanoma cell lines expressed Fast mRNA, Fast mRNA was abundantly expressed by antimelanoma T-cell lines after activation. These data do not support a role for Fast expression in the escape of melanoma cells from immune destruction.
引用
收藏
页码:59 / 62
页数:4
相关论文
共 23 条
[1]   Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts [J].
Allison, J ;
Georgiou, HM ;
Strasser, A ;
Vaux, DL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (08) :3943-3947
[2]   Gene transfer of Fas ligand induces tumor regression in vivo [J].
Arai, H ;
Gordon, D ;
Nabel, EG ;
Nabel, GJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (25) :13862-13867
[3]   A modification of the JAM test is necessary for a correct determination of apoptosis induced by FasL+ adherent tumor cells [J].
Böhm, C ;
Hanski, ML ;
Gratchev, A ;
Mann, B ;
Moyer, MP ;
Riecken, EO ;
Hanski, C .
JOURNAL OF IMMUNOLOGICAL METHODS, 1998, 217 (1-2) :71-78
[4]   Regulation of the proinflammatory effects of Fas ligand (CD95L) [J].
Chen, JJ ;
Sun, YN ;
Nabel, GJ .
SCIENCE, 1998, 282 (5394) :1714-1717
[5]  
Correa MR, 1997, J IMMUNOL, V158, P5292
[6]  
Ehl S, 1996, J IMMUNOL, V156, P2357
[7]   Danger versus tolerance: Paradigms for future studies of tumor-specific cytotoxic T lymphocytes [J].
Fenton, RG ;
Longo, DL .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (04) :272-275
[8]  
FIEDLER P, 1998, SCIENCE, V279, pA2015
[9]   Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape [J].
Hahne, M ;
Rimoldi, D ;
Schroter, M ;
Romero, P ;
Schreier, M ;
French, LE ;
Schneider, P ;
Bornand, T ;
Fontana, A ;
Lienard, D ;
Cerottini, JC ;
Tschopp, J .
SCIENCE, 1996, 274 (5291) :1363-1366
[10]   Tumor vaccines -: A reality at last? [J].
Hellström, I ;
Hellström, KE .
JOURNAL OF IMMUNOTHERAPY, 1998, 21 (02) :119-126